Molecular Targeted Agents in Non–Small-Cell Lung Cancer
AB Sandler - Clinical Lung Cancer, 2003 - Elsevier
Although advances in chemotherapy have provided some improvement in overall survival
for patients with advanced non–small-cell lung cancer (NSCLC), outcomes remain poor …
for patients with advanced non–small-cell lung cancer (NSCLC), outcomes remain poor …
Molecular Targeted Agents in Non–Small-Cell Lung Cancer
AB Sandler - Clinical Lung Cancer, 2003 - clinical-lung-cancer.com
Although advances in chemotherapy have provided some improvement in overall survival
for patients with advanced non–small-cell lung cancer (NSCLC), outcomes remain poor …
for patients with advanced non–small-cell lung cancer (NSCLC), outcomes remain poor …
Molecular Targeted Agents in Non–Small-Cell Lung Cancer
AB Sandler - Clinical Lung Cancer, 2003 - infona.pl
Although advances in chemotherapy have provided some improvement in overall survival
for patients with advanced non–small-cell lung cancer (NSCLC), outcomes remain poor …
for patients with advanced non–small-cell lung cancer (NSCLC), outcomes remain poor …
Molecular targeted agents in non-small-cell lung cancer
AB Sandler - Clinical lung cancer, 2003 - pubmed.ncbi.nlm.nih.gov
Although advances in chemotherapy have provided some improvement in overall survival
for patients with advanced non-small-cell lung cancer (NSCLC), outcomes remain poor …
for patients with advanced non-small-cell lung cancer (NSCLC), outcomes remain poor …
Molecular targeted agents in non-small-cell lung cancer.
AB Sandler - Clinical Lung Cancer, 2003 - europepmc.org
Although advances in chemotherapy have provided some improvement in overall survival
for patients with advanced non-small-cell lung cancer (NSCLC), outcomes remain poor …
for patients with advanced non-small-cell lung cancer (NSCLC), outcomes remain poor …